Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC trimmed its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 7.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,492 shares of the company’s stock after selling 1,090 shares during the period. Legato Capital Management LLC’s holdings in Enliven Therapeutics were worth $304,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after buying an additional 3,559 shares during the period. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter valued at about $256,000. Verition Fund Management LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter valued at about $271,000. The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics in the 2nd quarter worth approximately $322,000. Finally, Quest Partners LLC raised its holdings in shares of Enliven Therapeutics by 1,226.4% in the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock worth $539,000 after purchasing an additional 19,525 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on ELVN shares. Robert W. Baird raised their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Price Performance

ELVN stock opened at $21.68 on Friday. The company’s 50 day simple moving average is $22.60 and its 200-day simple moving average is $24.13. Enliven Therapeutics, Inc. has a 52-week low of $10.90 and a 52-week high of $30.03. The firm has a market capitalization of $1.06 billion, a P/E ratio of -11.41 and a beta of 1.03.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 21,700 shares of Enliven Therapeutics stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50. The disclosure for this sale can be found here. Insiders have sold a total of 43,117 shares of company stock valued at $1,013,775 in the last three months. 29.20% of the stock is currently owned by company insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.